Tag
The FOREST-HCM long-term study confirms aficamten’s efficacy and safety in reducing left ventricular outflow tract obstruction and improving symptoms in obstructive hypertrophic cardiomyopathy over nearly one year of treatment.
A multicenter trial demonstrates that aficamten monotherapy outperforms metoprolol in improving exercise capacity and symptoms in obstructive hypertrophic cardiomyopathy (HCM).
Aficamten significantly improves exercise capacity and symptoms in obstructive hypertrophic cardiomyopathy (HCM), demonstrating robust efficacy and safety in both mildly and severely symptomatic patients.
Aficamten shows sustained obstruction relief, symptom improvement, and favorable cardiac remodeling over 48 weeks in obstructive hypertrophic cardiomyopathy, with safe discontinuation of disopyramide possible.
